Systemic Sclerosis - Global Drug Forecast and Market Analysis to 2030
June 11, 2021 03:19 ET
|
ReportLinker
New York, June 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Systemic Sclerosis - Global Drug Forecast and Market Analysis to 2030" -...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
June 11, 2021 03:09 ET
|
UBISOFT ENTERTAINMENT
Le 11 juin 2021 Ubisoft - Actions et droits de vote - 31.05.2021 Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Article 223-16 du...
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
June 11, 2021 03:05 ET
|
Global Blood Therapeutics, Inc.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress
June 11, 2021 03:03 ET
|
Immunicum AB
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress -- Ongoing ADVANCE II study evaluating DCP-001 in AML patients is nearing...
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
June 11, 2021 03:00 ET
|
Global Blood Therapeutics, Inc.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
June 11, 2021 03:00 ET
|
X4 Pharmaceuticals
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström’s patients; meaningful increases in hemoglobin...
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
June 11, 2021 03:00 ET
|
Agios Pharmaceuticals, Inc.
– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 – – Mitapivat Safety Profile Consistent with Previously...
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 11, 2021 03:00 ET
|
Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
June 11, 2021 03:00 ET
|
Novartis Pharma AG
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal...
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
June 11, 2021 03:00 ET
|
Agios Pharmaceuticals, Inc.
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast...
- September 27, 2024 05:01 ET Canada Alternative Lending Business Report 2024: Market to Grow by 26% to reach $2.17 Billion this Year - Product Launches and Innovations, Regulatory Changes, Mergers and Acquisitions to 2029
- September 27, 2024 04:52 ET United States Alternative Lending Business Report 2024: Market to Reach $378.61 Billion by 2028 from $255.39 Billion in 2023 - Innovation, Partnerships, and Mergers Shape the Future